SCHEMBL31015013

SCHEMBL31015013

C[C@@H]1CCN(c2cncc(Cl)n2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
CYP1A2 P05177 2/20 0.53
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53
CYP3A4 P08684 1/20 0.53
HTR1A P08908 1/20 0.53
CYP2C9 P11712 1/20 0.53
HPGD P15428 1/20 0.53
HTR2A P28223 1/20 0.53
HTR2C P28335 1/20 0.53
CYP2C19 P33261 1/20 0.53
HSD17B10 Q99714 1/20 0.53
SMPD3 Q9NY59 2/20 0.44
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
CYP2D6 P10635 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
NFKB1 P19838 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31015395 1.00 KMT2A (0.53) KMT2AMEN1CYP1A2KDM4EALDH1A1
SCHEMBL31015425 0.82 MEN1 (0.54) KMT2AMEN1CYP1A2KDM4EALDH1A1
SCHEMBL31015362 0.82 MEN1 (0.54) KMT2AMEN1CYP1A2KDM4EALDH1A1
SCHEMBL7394710 0.81 MEN1 (0.53) KMT2AMEN1CYP1A2KDM4EALDH1A1
SCHEMBL31396174 0.80 KDM4E (0.49) KMT2AMEN1CYP1A2KDM4EALDH1A1
Hydrochloric Acid SCHEMBL9005365 0.79 MEN1 (0.51) KMT2AMEN1CYP1A2KDM4EALDH1A1
SCHEMBL12410836 0.78 HRH4 (0.42) SMPD3
SCHEMBL26141056 0.78 HRH4 (0.42) SMPD3
SCHEMBL12988378 0.77 MEN1 (0.57) KMT2AMEN1CYP1A2KDM4EALDH1A1
SCHEMBL29161360 0.77 MEN1 (0.60) KMT2AMEN1CYP1A2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2025-01-02 US disclosed
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors EPICS THERAPEUTICS (BE) 2024-09-17 US disclosed
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2024-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 KMT2A 208/4885MEN1 1196/4885CYP1A2 2618/4885
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 KMT2A 208/4885MEN1 1196/4885CYP1A2 2618/4885
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors METTL3, METTL16, DIMT1 KMT2A 208/4885MEN1 1196/4885CYP1A2 2618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.